ScholarLens Back to search
2002•Zhongguo aizheng zazhiRequires access

Paclitaxel and platinum-containing chemotherapy in 16 cases with advanced epithelial ovarian cancer

Cong Li

Open publisher page 0 citations

Abstract

Purpose:To evaluate the therapeutic effect of paclitaxel and platinum containing chemotherapy (cisplatin or carboplatin) in women with epithelial ovarian cancer.Methods:We assigned 16 cases with advanced epithelial ovarian cancer after initial surgery to receive paclitaxel and cisplatin or carboplatin. Pcalitaxel (135 mg/m 2,over a period of 10 hours ) was administered iv once every 3 to 4 weeks, 24 control cases were treated with CAP or CVP regimen. Results:The overall median survival was significantly longer in the paclitaxel platinum group than in the cisplatin cyclophosphamide group (median, 35 vs. 22.5 months, P 0.025). Among 16 women with measurable disease, 75 percent in the TP group responsed to therapy, as compared with 41.7 percent in the CP group ( P 0.05). Conclusions:Paclitazel and platinum agent are effective in the treatment of advanced epithelial ovarian cancer.

About this research paper

What this paper is about

Purpose:To evaluate the therapeutic effect of paclitaxel and platinum containing chemotherapy (cisplatin or carboplatin) in women with epithelial ovarian cancer.Methods:We assigned 16 cases with advanced epithelial ovarian cancer after initial surgery to receive paclitaxel and cisplatin or carboplatin. Pcalitaxel (135 mg/m 2,over a period of 10 hours ) was administered iv once every 3 to 4 weeks, 24 control cases were treated with CAP or CVP regimen. Results:The overall median survival was significantly longer in the paclitaxel platinum group than in the cisplatin cyclophosphamide group (median, 35 vs. 22.5 months, P 0.025). Among 16 women with measurable disease, 75 percent in the TP group responsed to therapy, as compared with 41.7 percent in the CP group ( P 0.05). Conclusions:Paclitazel and platinum agent are effective in the treatment of advanced epithelial ovarian cancer.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Purpose:To evaluate the therapeutic effect of paclitaxel and platinum containing chemotherapy (cisplatin or carboplatin) in women with epithelial ovarian cancer.Methods:We assigned 16 cases with advanced epithelial ovarian cancer after initial surgery to receive paclitaxel and cisplatin or carboplatin. Pcalitaxel (135 mg/m 2,over a period of 10 hours ) was administered iv once every 3 to 4 weeks, 24 control cases were treated with CAP or CVP regimen. Results:The overall median survival was significantly longer in the paclitaxel platinum group than in the cisplatin cyclophosphamide group (median, 35 vs. 22.5 months, P 0.025). Among 16 women with measurable disease, 75 percent in the TP group responsed to therapy, as compared with 41.7 percent in the CP group ( P 0.05). Conclusions:Paclitazel and platinum agent are effective in the treatment of advanced epithelial ovarian cancer.

Key concepts: Carboplatin, Paclitaxel, Cisplatin, Regimen, Medicine, Chemotherapy, Epithelial ovarian cancer, Ovarian cancer

Back to paper searchBrowse research topicsOriginal source
Paclitaxel and platinum-containing chemotherapy in 16 cases with advanced epithelial ovarian cancer — Research Paper | ScholarLens